<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536380</url>
  </required_header>
  <id_info>
    <org_study_id>P04849</org_study_id>
    <nct_id>NCT00536380</nct_id>
  </id_info>
  <brief_title>Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)</brief_title>
  <official_title>A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20
      mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria.
      Subjects with chronic urticaria who are currently taking a second generation antihistamine
      will be treated with desloratadine (5, 10, or 20 mg) for 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg</measure>
    <time_frame>Baseline and 4 treatment weeks</time_frame>
    <description>The UAS is a composite diary-recorded score. The diary recorded scores included wheal score and pruritus score with numeric severity intensity ratings of 0 = none to 3 = intense. The scoring was to be done twice daily within one hour of arising and in the evening, approximately 12 hours later. Scoring was &quot;reflective&quot;, covering the 12-hour period since the previous recording. The daily UAS is the average of the morning and evening scores. The final week by definition was the terminal week. It was the last week participants stayed for the treatment period.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Chronic Idiopathic Urticaria</condition>
  <arm_group>
    <arm_group_label>5-mg Desloratadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-mg Desloratadine once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-mg Desloratadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-mg Desloratadine once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20-mg Desloratadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-mg Desloratadine once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-mg Desloratadine</intervention_name>
    <description>5-mg desloratadine tablets, once daily for four weeks.</description>
    <arm_group_label>5-mg Desloratadine</arm_group_label>
    <other_name>SCH 34117, Clarinex, Aerius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-mg Desloratadine</intervention_name>
    <description>10-mg desloratadine tablets, once daily for four weeks.</description>
    <arm_group_label>10-mg Desloratadine</arm_group_label>
    <other_name>SCH 34117, Clarinex, Aerius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20-mg Desloratadine</intervention_name>
    <description>20-mg desloratadine tablets, once daily for four weeks.</description>
    <arm_group_label>20-mg Desloratadine</arm_group_label>
    <other_name>SCH 34117, Clarinex, Aerius</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must satisfy the following criteria before being enrolled/randomized into the
             study.

          -  Subject must demonstrate willingness to participate in the study.

          -  Subject must be 18 to 75 years of age, of either gender, and any race.

          -  Subject must have had this episode of chronic idiopathic urticaria for at least 6
             weeks or more, and has been dosing with a &quot;2nd generation antihistamine (AH)&quot; for 2
             weeks or longer, and

          -  Subject's current episode of urticaria is sufficiently symptomatic at the Screening
             Visit to qualify for this study, in the opinion of the investigator.

          -  Subject has a Baseline Week (entry period) UAS between 10 and 30 inclusive.

          -  Patient must understand and be willing to assess and record symptom scores.

          -  Has voluntarily signed a written informed consent.

          -  Subjects must confirm that all prior medication washout times have been observed.

          -  Subject must confirm that he/she is practicing adequate contraception:

        Female volunteers of childbearing potential (including women who are less than 1 year
        postmenopausal and women who will be sexually active during the study) must agree to use a
        medically accepted method of contraception or be surgically sterilized prior to screening,
        while receiving protocol-specified medication, and for 30 days after stopping the
        medication. Women who are postmenopausal for &gt;1 year (i.e., women who have experienced 12
        consecutive months of amenorrhea) will be exempted from the use of contraception during the
        study. Nonsterile or premenopausal female subjects must be using a medically accepted
        method of birth control, ie, double-barrier method (eg, male or female condom and
        spermicide), oral contraceptive, Depo-Provera, NuvaRing, contraceptive transdermal patch,
        etc, for female subjects of childbearing potential prior to screening and during the study.
        Women of childbearing potential should be counseled in the appropriate use of birth control
        while in the study. Vasectomy or tubal ligation is considered a single barrier. Women who
        are not currently sexually active must agree and consent to use one of the above-mentioned
        methods if they become sexually active while participating in the study.

          -  If subject is a female volunteer of childbearing potential, she must have a negative
             urine pregnancy test at Screening/Visit 1.

          -  Subjects must be free of any clinically relevant disease other than chronic idiopathic
             urticaria (CIU) that would, in the principal investigator's and/or sponsor's opinion,
             interfere with the conduct of the study or study evaluations.

          -  Subjects must be able to adhere to the dosing and visit schedules and agree to record
             symptom severity scores, medication times, concomitant medications, and adverse events
             (AEs) accurately and consistently in a daily diary.

        Exclusion Criteria:

          -  Is a female who is pregnant, or intends to become pregnant during the study.

          -  Is nursing, or intends to be nursing during the study or within 90 days after study
             completion.

          -  Has not observed the designated washout periods for any of the prohibited medications.

          -  Has used any investigational product within 30 days prior to enrollment.

          -  Have any of the following clinical conditions:

               -  Symptomatic seasonal or perennial allergic rhinitis.

               -  Asthma not controlled by short-acting beta-2 agonists used as necessary.

               -  The presence of permanent severe diseases, especially those affecting the immune
                  system, except urticaria.

               -  The presence of a permanent gastrointestinal condition which may influence the
                  oral therapy (chronic diarrhea diseases, congenital malformations or surgical
                  mutilations of gastrointestinal tract).

               -  History of/or presence of epilepsy, significant neurological disorders,
                  cerebrovascular attacks or ischemia.

               -  History of/or presence of myocardial infarction or cardiac arrhythmia which
                  requires drug therapy.

               -  Evidence of/or a history of significant renal disease.

               -  Evidence of/or a history of significant hepatic disease.

               -  Presence of cancer which requires chemotherapy or radiation therapy.

               -  Presence of glaucoma.

               -  Presence of urinary bladder neck obstruction with emptying difficulties.

               -  Presence of acute urticaria .

               -  Body mass index (BMI) &gt; 35

          -  Has any clinically significant deviation from the appropriate reference range in the
             physical examination, or other clinical evaluation that, in the investigator's
             judgment, may interfere with the study evaluation or affect subject safety.

          -  Is in a situation or condition that, in the opinion of the investigator, may interfere
             with optimal participation in the study.

          -  Is participating in any other clinical study(ies).

          -  Is on the staff, affiliated with, or a family member of the staff personnel directly
             involved with this study.

          -  Is allergic to or has a history of hypersensitivity to the study drug (desloratadine),
             to any of its excipients, or to loratadine.

          -  Has the rare hereditary problem of galactose intolerance, the Lapp lactase deficiency,
             or glucose-galactose malabsorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <results_first_submitted>February 24, 2010</results_first_submitted>
  <results_first_submitted_qc>April 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2010</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5-mg Desloratadine</title>
          <description>5-mg Desloratadine once daily</description>
        </group>
        <group group_id="P2">
          <title>10-mg Desloratadine</title>
          <description>10-mg Desloratadine once daily</description>
        </group>
        <group group_id="P3">
          <title>20-mg Desloratadine</title>
          <description>20-mg Desloratadine once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5-mg Desloratadine</title>
          <description>5-mg Desloratadine once daily</description>
        </group>
        <group group_id="B2">
          <title>10-mg Desloratadine</title>
          <description>10-mg Desloratadine once daily</description>
        </group>
        <group group_id="B3">
          <title>20-mg Desloratadine</title>
          <description>20-mg Desloratadine once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="12.8"/>
                    <measurement group_id="B2" value="40.4" spread="13.3"/>
                    <measurement group_id="B3" value="40.1" spread="14.2"/>
                    <measurement group_id="B4" value="40.6" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg</title>
        <description>The UAS is a composite diary-recorded score. The diary recorded scores included wheal score and pruritus score with numeric severity intensity ratings of 0 = none to 3 = intense. The scoring was to be done twice daily within one hour of arising and in the evening, approximately 12 hours later. Scoring was “reflective”, covering the 12-hour period since the previous recording. The daily UAS is the average of the morning and evening scores. The final week by definition was the terminal week. It was the last week participants stayed for the treatment period.</description>
        <time_frame>Baseline and 4 treatment weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Desloratadine</title>
            <description>5-mg Desloratadine once daily</description>
          </group>
          <group group_id="O2">
            <title>20-mg Desloratadine</title>
            <description>20-mg Desloratadine once daily</description>
          </group>
          <group group_id="O3">
            <title>10-mg Desloratadine</title>
            <description>10-mg Desloratadine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg</title>
          <description>The UAS is a composite diary-recorded score. The diary recorded scores included wheal score and pruritus score with numeric severity intensity ratings of 0 = none to 3 = intense. The scoring was to be done twice daily within one hour of arising and in the evening, approximately 12 hours later. Scoring was “reflective”, covering the 12-hour period since the previous recording. The daily UAS is the average of the morning and evening scores. The final week by definition was the terminal week. It was the last week participants stayed for the treatment period.</description>
          <population>Intent to treat population</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline in UAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.12"/>
                    <measurement group_id="O2" value="-1.0" spread="0.12"/>
                    <measurement group_id="O3" value="-1.1" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline UAS (mean +/- standard deviation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.82"/>
                    <measurement group_id="O2" value="2.8" spread="0.74"/>
                    <measurement group_id="O3" value="2.9" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.721</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5-mg Desloratadine</title>
          <description>5-mg Desloratadine once daily</description>
        </group>
        <group group_id="E2">
          <title>10-mg Desloratadine</title>
          <description>10-mg Desloratadine once daily</description>
        </group>
        <group group_id="E3">
          <title>20-mg Desloratadine</title>
          <description>20-mg Desloratadine once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI agrees not to publish or publicly present any interim results of Study without prior written consent of sponsor. PI further agrees to provide 45 days written notice to sponsor prior to submission for publication or presentation to permit sponsor to review copies of abstracts or manuscripts for publication (including, without limitation, slides and text of oral or other public presentations and text of any transmission through any electronic media) which report any results of Study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to poor enrollment (even after extending the enrollment period), only 314 participants (not 600 participants) were randomized to the study and hence the study was inconclusive due to the lacking of statistical power and robustness.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

